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Abstract
Background The commercial formulation of sumatriptan nasal spray is an effective option for migraine patients requiring 
or preferring a non-oral route of drug administration, but its utility is limited by poor absorption and tolerability issues. 
DFN-02, a new formulation of sumatriptan 10 mg nasal spray, is co-formulated with a permeation enhancer that gives it 
pharmacokinetics comparable to subcutaneous sumatriptan. As reported previously, DFN-02 was significantly better than 
placebo on multiple efficacy endpoints at 2 h postdose, including pain freedom, absence of the most bothersome symptom, 
and pain relief, and its safety and tolerability profiles were excellent.
Objective The objective of this study was to assess the efficacy of acute treatment of migraine with DFN-02, including its 
effect on migraine-related functional disability and patient satisfaction with treatment.
Methods This was a multicenter, randomized, double-blind, placebo-controlled efficacy and safety study of DFN-02 in adults 
with episodic migraine. Functional disability and subject satisfaction with treatment were prespecified endpoints, assessed 
in real-time by subjects, using an electronic diary.
Results In total, 107 subjects were randomized. DFN-02 was significantly superior to placebo for the reduction in functional dis-
ability score from predose level at 2 h after treatment (− 1.2 vs. − 0.6, p < 0.001). Subjects treated with DFN-02 were also more 
likely to be satisfied or very satisfied than subjects treated with placebo at 2 h postdose (70.0% vs. 44.2%, p = 0.027). Using the 
Patient Perception of Migraine Questionnaire-Revised at 24 h postdose, DFN-02 mean scores were significantly superior to placebo 
for the subscales of efficacy (65.2 vs. 42.5, p = 0.016) and function (68.9 vs. 42.1, p = 0.001), and for total score (71.0 vs. 56.6, 
p = 0.016); global medication effectiveness (p = 0.027); and overall satisfaction (p = 0.019). Placebo was significantly better than 
DFN-02 on the tolerability subscale (94.8 vs. 88.5, p = 0.026). At 24 h postdose, subjects reported significantly higher satisfac-
tion with DFN-02 compared with satisfaction reported pre-randomization regarding their usual migraine medication (p = 0.012).
Conclusion DFN-02 was superior to placebo for the relief of migraine-related functional disability, and provided greater 
satisfaction than placebo or subjects’ usual acute treatment.
Trial Registration ClinicalTrials.gov identifier: NCT02856802.
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2 Promius Pharma, A Subsidiary of Dr. Reddy’s Laboratories, 
Princeton, NJ, USA
3 The David Geffen School of Medicine at UCLA, 
Los Angeles, CA, USA
Key Points 
This was a multicenter, randomized, double-blind, 
placebo-controlled efficacy and safety study of DFN-
02, sumatriptan 10 mg nasal spray with permeation 
enhancer, in adults with episodic migraine.
DFN-02 was more effective than placebo for the relief of 
functional disability associated with migraine.
Subjects were more satisfied with DFN-02 than with 
their usual acute treatment.
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relief, absence of the most bothersome symptom (MBS), and 
freedom from associated symptoms at 2 h postdose, with an 
excellent tolerability profile [21]. Despite a growing body of 
research with DFN-02, the capacity to relieve functional dis-
ability and the degree of subject satisfaction associated with 
DFN-02 treatment have not been evaluated. Accordingly, 
the objective of the present study in adults with episodic 
migraine was to compare DFN-02 with placebo for acute 
relief of functional disability and with usual treatment for 
subject-rated treatment satisfaction.
2  Methods
The methods for this study (NCT02856802) have been 
described in detail elsewhere [21].
2.1  Subjects
To qualify, subjects had to be adults aged 18–75 years with 
episodic migraine meeting the criteria of the International 
Classification of Headache Disorders, 3rd edition (beta ver-
sion; ICHD-3 beta) [22]. They also had to have a 12-month 
history of two to eight attacks per month, with 14 or fewer 
headache days monthly and at least 48 h of headache-free 
time between attacks. Subjects were excluded if they had 
medication-overuse headache (as defined by ICHD-3 beta); 
used any botulinum toxin treatment within 120 days of 
screening; changed doses of migraine preventive medica-
tions during the 30 days before and through screening; took 
miniprophylaxis for menstrual migraine; or had a health con-
dition likely to affect the physiology of the nasal mucosa 
or any pathology that might interfere with treatment or the 
outcomes of the study.
2.2  Treatments
DFN-02 and matching placebo spray (manufactured by 
Renaissance, Lakewood, NJ, USA) were provided in single-
use intranasal spray devices designed to deliver 100 μL/spray 
containing either 10 mg of sumatriptan plus 0.20% DDM or 
placebo containing 0.20% DDM but no sumatriptan.
2.3  Study Conduct
The study included four visits: screening, baseline/rand-
omization, end of the first double-blind treatment period/
re-randomization into a second double-blind treatment 
period, and end of the study/early termination. At screen-
ing, subjects signed informed consent; had a medical history 
and physical examination; and were assessed for vital signs, 
serology, urine pregnancy test, clinical laboratory tests, 
urinalysis, urine drug test, and 12-lead electrocardiogram 
1 Introduction
Although migraine-related disability and patient satisfaction 
are infrequently discussed during consultations for headache 
[1–3], both are considered important components of efficacy 
in clinical trials [4]. In fact, relief of headache-related dis-
ability is among the most important goals of acute treat-
ment [5]. Patients consistently rate restoration of function 
among the most valued attributes of acute medication [6–8]; 
the severity of migraine-related disability is predictive of 
dissatisfaction with acute treatment [9]. Information about 
functional disability influences drug selection by medical 
professionals [1].
Sumatriptan has been the predominant prescription 
migraine-specific acute treatment since 1992 [10, 11]. 
Although the subcutaneous injections are recognized as the 
fastest and most effective form of acute migraine treatment 
[12], most patients prefer tablets because they are familiar, 
easy to use, and associated with fewer adverse effects than 
injections. Guidelines for the acute treatment of migraine 
recommend subcutaneous injections or nasal spray for-
mulations for patients who do not respond to oral triptans, 
patients with prominent gastrointestinal symptoms that inter-
fere with orally administered acute treatments, and those for 
whom oral therapies are intolerable due to treatment-emer-
gent nausea or dysphagia [5, 13]. Since many individuals 
dislike injections, other non-oral treatment approaches are 
used in people with needs unmet by oral therapy. One option, 
sumatriptan nasal spray, is effective and well-tolerated for 
the acute treatment of migraine [14–16], but its onset of 
action (30–45 min) is variable, suboptimal, and comparable 
to oral tablets [17]. This may reflect limited nasal absorption 
[16]; peak plasma concentration is not reached for 1.75 h 
postdose [18]. Dysgeusia is a frequent adverse effect that 
limits its use [14].
DFN-02 (sumatriptan 10 mg plus 0.20% 1-O-n-Dodecyl-
β-d-Maltopyranoside [DDM]; Promius Pharma, Princeton, 
NJ, USA) is an intranasal migraine medication that was 
designed to address the shortcomings of the commercially 
available formulation of sumatriptan nasal spray. Its active 
ingredient, sumatriptan, has been comprehensively analyzed 
in the past. The permeation-enhancing effects of the DDM 
excipient in intranasal formulations are based on its effects 
on mucosal viscosity and membrane fluidity, which relax 
cell–cell junctions and facilitate drug transport across the 
nasal epithelium. DFN-02 has previously demonstrated 
absorption into the systemic circulation 5 min faster than 
the 4 and 6 mg subcutaneous doses of sumatriptan [19], 
and it had good tolerability in a 6-month safety study in 
adults with episodic migraine [20]. Additionally, DFN-02 
was evaluated in adults with migraine and was shown to 
be significantly better than placebo for pain freedom, pain 
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(ECG). Hematology, clinical chemistry, urinalysis, urine 
drug screen, and human immunodeficiency virus, hepatitis 
B surface antigen, and hepatitis C virus antibody analyses 
were performed by Eurofins Central Laboratory (Lancas-
ter, PA, USA). For qualified subjects, the investigator or 
designee contacted the designated interactive web response 
system to obtain a unique patient identification number for 
use throughout the study. Subjects were trained on how to 
enter migraine and study medication data into a real-time 
electronic diary (eDiary). The eDiary was dispensed at 
screening for subjects to enter at least one migraine attack 
to ensure their comfort and compliance with the device. Sub-
jects continued to take their normal migraine medication 
during the screening period, which lasted up to 21 days to 
ensure that they met the eligibility criteria. Once eligibility 
for enrollment was confirmed, the investigator or designee 
contacted the interactive web response system centralized 
randomization center to receive the blinded study medica-
tion kit assignment.
At baseline, subjects were randomized (1:1) to receive 
DFN-02 or matching placebo. Study site staff instructed sub-
jects in the proper self-administration of study medication 
and subjects were confirmed to have, or were provided with, 
written instructions for use.
In the first double-blind treatment period, subjects were 
instructed to use one nasal spray device to treat a single 
migraine attack as soon as (and no more than 1 h after) they 
experienced migraine pain of moderate to severe intensity. 
If subjects were unable to use study medication for the first 
attack after randomization, they were instructed to use the 
study medication for the next qualifying attack. Subjects 
were permitted to take a second dose of study medication 
or rescue medication if they failed to experience sufficient 
relief from the first dose within 2 h and they had recorded a 
2-h postdose assessment in the eDiary. The choice of rescue 
medication was made by investigators and subjects, and no 
more than two doses of study medication were permitted 
within a 24-h period.
Subjects who treated an attack and recorded their 
response to medication in an eDiary were re-randomized 
into a second double-blind treatment period in which they 
treated a second migraine attack at any level of pain inten-
sity. The study was powered and data are presented for the 
first double-blind treatment period. After they were rand-
omized, subjects could participate in the study for no more 
than 10 weeks.
Subjects recorded information about their attacks, the 
effects of study medication on functional disability, and sat-
isfaction with treatment, in the eDiary; other data, such as 
safety and tolerability, were entered by site staff into elec-
tronic case report forms. After study completion or discon-
tinuation, subjects were referred to their usual healthcare 
professional to continue treatment of migraine and other 
conditions.
2.4  Assessments
This report presents the results of the DFN-02 comparison 
with placebo on the efficacy endpoints of functional disabil-
ity and subject satisfaction with treatment at 2 h and 24 h 
postdose. Other efficacy data from this study, including data 
on the endpoints of pain freedom, pain relief, and absence of 
the MBS, have been presented elsewhere [21].
Functional disability was assessed at predose, 2 h post-
dose, and 24 h postdose on a scale where 0 = no disability, 
able to function normally; 1 = performance of daily activities 
mildly impaired, could still do everything but with difficulty; 
2 = performance of daily activities moderately impaired, 
unable to do some things; and 3 = performance of daily 
activities severely impaired, unable to do most things, bed 
rest may have been necessary [4]. Satisfaction with treatment 
at 2 h postdose was evaluated on a 7-point Likert-type scale 
[23], where 1 = very satisfied, 2 = satisfied, 3 = somewhat 
satisfied, 4 = neither satisfied nor dissatisfied, 5 = somewhat 
dissatisfied, 6 = dissatisfied, and 7 = very dissatisfied. Scores 
were categorized as satisfied (1–3), satisfied/neither (1–4), 
neither/dissatisfied (4–7), and dissatisfied (5–7), and the 
degree of subject satisfaction with treatment was defined by 
these categories.
The Patient Perception of Migraine Questionnaire-
Revised (PPMQ-R) [24, 25] was used at baseline (pre-
randomization) to assess subjects’ satisfaction with their 
usual pre-study migraine treatment, and was also used at 
24 h postdose to assess subjects’ satisfaction with the study 
medication. The PPMQ-R scale comprised items for effi-
cacy (11 questions), function (4 questions), ease of use (2 
questions), and tolerability (10 questions). Cost-related 
items were excluded because there was no charge for study 
medication. Three global items measured subject satisfac-
tion in terms of medication effectiveness, adverse effects, 
and overall satisfaction. The total score was comprised 
of the efficacy, function, and ease of use subscale scores. 
The tolerability of adverse effects (i.e. bothersomeness of 
adverse effects) was scored on a 5-point Likert-type scale 
that ranged from 1 (not bothersome at all) to 5 (extremely 
bothersome). Each PPMQ-R subscale score and the total 
score were transformed to range from 0 to 100 by subtract-
ing the lowest possible scale score, dividing the range of the 
scale, and multiplying by 100, with higher scores indicating 
better satisfaction or tolerability. For the transformed scale, 
higher scores mean greater satisfaction. The total raw score 
and the three global items were not transformed, and there-
fore lower scores denote better satisfaction. If a response was 
missing, the particular subscale or global item was consid-
ered non-evaluable. If a subscale or global item was deemed 
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non-evaluable or missing, the corresponding total score was 
also considered non-evaluable.
Safety variables included the incidence of adverse events 
(AEs), clinical laboratory data (hematology, chemistry, and 
urinalysis), vital sign measurements (sitting blood pressure, 
pulse, respiration rate, and body temperature), physical 
examination findings, 12-lead ECG readings, urine preg-
nancy test results, study medication use, and concomitant 
medication use. The safety endpoint assessments included 
tolerability as assessed by AEs for each treatment period, 
and overall and safety as assessed by clinical laboratory 
tests, vital signs, and ECGs for each treatment period and 
overall.
Adverse events were coded using the Medical Diction-
ary for Regulatory Activities (MedDRA, version 19.0) and 
classified by severity (mild, moderate, severe) and causal-
ity (not related, possibly related, probably related, definitely 
related). Severe AEs were defined as AEs that prevented 
normal everyday activities and usually needed treatment 
or other intervention. Investigators also characterized the 
seriousness of AEs, and serious AEs (SAE) were defined 
as any untoward medical occurrences or effects that, at any 
dose, resulted in death or were life-threatening, required or 
prolonged inpatient hospitalization, resulted in persistent or 
significant disability/incapacity, or were congenital anomaly/
birth defects. Not all severe AEs were SAEs.
2.5  Statistics
The study populations for analysis included all subjects who 
were screened (for disposition), all randomized subjects who 
took at least one dose of study medication and had at least 
one postbaseline efficacy time point (for efficacy), and all 
subjects who received at least one dose of study medication 
(for safety). Data presented are based on a statistical analysis 
plan with prespecified endpoints, except for two data points 
(percentage of subjects with no disability, and percentage 
of subjects with mild/no disability), which were analyzed 
post hoc. Analyses and summaries were produced using SAS 
version 9.3 or above (SAS Institute, Cary, NC, USA).
Analyses on quantitative and categorical variables 
included data from subjects with non-missing values, and 
missing or incomplete data were imputed only for summa-
ries of AEs. Unless specified otherwise, all statistical test-
ing and confidence intervals (CIs) were two-sided and were 
performed using a significance (alpha) level of 0.05. For 
analyses of functional disability, the number of subjects with 
response, the number of subjects with non-missing assess-
ments, proportions for the DFN-02 and placebo groups, 95% 
exact CIs for those proportions, the odds ratio for response, 
and the corresponding p values from Fisher’s exact test were 
computed for comparisons between the treatment groups. 
For the assessments of subject satisfaction, p values from the 
Wilcoxon rank-sum and signed-rank tests were computed.
3  Results
3.1  Subjects
Nine sites in the US participated in the study, which was 
conducted between 11 July 2016 and 10 February 2017. A 
total of 107 subjects met the inclusion criteria and was ran-
domized into the study; 93 (86.9%) subjects received at least 
one dose of study medication and had at least one postbase-
line efficacy assessment, and 86 (80.4%) subjects completed 
the study. In total, 21 (19.6%) subjects discontinued early. 
Subject disposition is presented in Table 1.
Most subjects were female (80.6%) and White (88.2%), 
and the mean age was 42.3  years (19–68). The mean 
weight was 78.5 kg (20.0), and the mean body mass index 
was 28.2 kg/m2 (6.9). Most subjects (78.5%) had never 
smoked.
The migraine history showed that subjects averaged 
three (24.7%) to four (23.7%) attacks per month, and 
53.8% had a history of migraine without aura. Nearly all 
subjects had a history of photophobia (98.9%) and phono-
phobia (93.5%) during attacks, with slightly lower propor-
tions reporting a history of nausea (86.0%).
Treatment history showed that usual migraine medica-
tion provided 34.4% of subjects with significant reductions 
in symptoms, 34.4% with slight reductions, 26.9% with 
complete relief, and 4.3% with no relief. Most subjects had 
their attacks significantly or completely resolved within 
1 h (30.1%) or 2 h (12.9%) of treatment. The most com-
monly used acute medications were ibuprofen (30.1%) 
Table 1  Disposition of subjects
a Four DFN-02 and 10 placebo subjects did not have the eDiary data
b As a result of non-compliance with the diary (DFN-02) and a posi-
tive test for cannabinoids at the baseline visit (placebo)
DFN-02 Placebo Total
Randomized 54 53 107
Analyzeda 50 43 93
Discontinued 6 15 21
 No migraine attack 2 6 8
 Subject withdrawal 1 5 6
 Lost to follow-up 2 0 2
 Other 0 2 2
 Terminated by  sponsorb 1 1 2
 Protocol deviation 0 1 1
 Use of non-permitted medication 0 0 0
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and caffeinated analgesic combinations (32.3%). A few 
subjects (11.8%) typically used sumatriptan.
3.2  Efficacy
3.2.1  Functional Disability
The mean change in score from baseline at 2 h postdose was 
significantly greater in the DFN-02 group than in the placebo 
group (− 1.2 vs. − 0.6, p < 0.001) (Fig. 1). Overall, 56.3% 
(27/48) of DFN-02 treated subjects had no functional dis-
ability compared with 28.2% (11/39) of placebo-treated sub-
jects (p = 0.01), and 83.3% (40/48) of subjects in the DFN-
02 group had mild or no functional disability compared with 
64.1% (25/39) of those in the placebo group (p = 0.05) at 2 h 
postdose. At 24 h postdose, there was no significant differ-
ence in disability scores between the treatment groups.
3.2.2  Treatment Satisfaction at 2 Hours Postdose
At 2 h postdose, mean (standard deviation) 2-h overall sub-
ject-rated treatment satisfaction scores were significantly 
better with DFN-02 than with placebo (2.8 [1.48] vs. 4.1 
[2.06], p = 0.003).
3.2.3  Perception of Migraine Questionnaire‑Revised
The results of the PPMQ-R completed by subjects in their 
eDiary at 24 h postdose are shown in Fig. 2. Subjects in the 
DFN-02 group were significantly more satisfied than those 
in the placebo group on the PPMQ-R subscales for efficacy 
(p = 0.016), function (p = 0.001), global items of medication 
effectiveness (p = 0.027), and overall satisfaction (p = 0.019), 
as well as on the total score (p = 0.016). The PPMQ-R toler-
ability subscale was significantly better for placebo than DFN-
02 (p = 0.026). There was no significant difference between 
the treatment groups for the subscale of ease of use and on the 
global item of adverse effects.
Among subjects treated with DFN-02, the treatment sat-
isfaction at 24 h postdose was significantly greater than sub-
jects’ satisfaction with their usual pre-study migraine medi-
cation, based on the baseline PPMQ-R for the total score 
(74.6 vs. 62.2, p = 0.012).
3.3  Safety
Safety data for this study have been reported previously [21]. 
Briefly, no SAEs or treatment-emergent AEs (TEAEs) lead-
ing to discontinuation from the study were reported, and 
there were no clinically meaningful changes in clinical labo-
ratory variables, vital signs, or ECG results.
Fig. 1  Change from baseline in functional disability scores at 2  h 
postdose
Fig. 2  Subject-rated treat-
ment satisfaction at 24 h 
postdose-PPMQ-R. aHigher 
values indicate greater satisfac-
tion. bLower values indicate 
greater satisfaction. PPMQ-R 
Patient Perception of Migraine 
Questionnaire-Revised
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4  Discussion
In this multicenter, randomized, double-blind, placebo-
controlled study, where subjects treated a migraine attack 
of moderate to severe headache and reported outcomes in a 
real-time eDiary, DFN-02 was significantly more effective 
than placebo for relief of functional disability and for subject 
satisfaction with treatment. DFN-02 subjects had a signifi-
cantly greater reduction in functional disability at 2 h post-
dose than placebo subjects, and the proportion of subjects 
with no disability at 2 h postdose was significantly higher in 
subjects treated with DFN-02 than in subjects treated with 
placebo. At 2 h postdose, a significantly greater proportion 
of subjects were satisfied with DFN-02 than with placebo. At 
24 h postdose, subject-rated satisfaction with DFN-02 was 
significantly higher than with placebo on multiple PPMQ-
R subscales, global items, and the total and raw scores, and 
with subjects’ usual treatment for acute relief of migraine.
Given the importance of restored function to migraine 
patients, the results with DFN-02 for relief of func-
tional disability are promising relative to findings from 
previous studies of the commercially available form of 
sumatriptan nasal spray. In two randomized, double-blind, 
parallel-group, multicenter studies with a 20 mg dose of 
the commercial formulation, 72–74% of subjects had mild 
or no disability at 2 h postdose [14]. In a randomized, 
double-blind, parallel-group, placebo-controlled study of 
the 20 mg commercial nasal spray, in which up to three 
migraine attacks were treated over a 6-month period, 70% 
of subjects had no or mild disability at 2 h postdose [15]. 
A meta-analysis of two studies (n = 225) with sumatriptan 
20 mg found that 62% of subjects had mild or no func-
tional disability at 2 h postdose [14, 16]. In the present 
study, 83.3% of DFN-02 subjects had mild or no func-
tional disability and, perhaps more clinically relevant 
(albeit unreported in previous studies), 56.3% were free 
from disability at 2 h postdose.
Overall, nearly one third of patients with migraine are dis-
satisfied with their usual acute medication [9]. Prior assess-
ments of satisfaction with sumatriptan nasal spray in adults 
compare it with the oral tablet and injectable forms [26], 
or they evaluate satisfaction with multiple formulations of 
sumatriptan prescribed simultaneously [27]. However, in a 
12-week study of sumatriptan 20 mg nasal spray in subjects 
whose attacks did not respond to first-line therapy, 60% of 
subjects preferred sumatriptan nasal spray 20 mg to their 
usual treatment [28]. Following treatment with DFN-02, 
70–78% of subjects treated with DFN-02 were satisfied with 
treatment, and subjects were significantly more satisfied with 
DFN-02 than with placebo, and with usual treatment at 2 and 
24 h after treatment.
DFN-02 showed excellent tolerability in this study. A 
prior meta-analysis of two studies (n = 516) found that the 
proportion of subjects who experienced any AE within 
24 h following sumatriptan 20 mg was 38% (vs. 9.7% with 
DFN-02), and the rate of the most common adverse effect 
with intranasal formulations, dysgeusia, was 27% [16] (vs. 
2.0–8.1% with DFN-02 [21]). Treatment-emergent nau-
sea, which can be the clinical rationale for recommending 
a trial of an intranasal spray [5], affected 19% of subjects 
in previous research [16], but was not reported with DFN-
02. Although comparing results from studies with different 
methodologies and populations does not allow for definite 
conclusions, DFN-02 does appear to offer improved toler-
ability relative to the original form of sumatriptan nasal 
spray. Accordingly, DFN-02 may be particularly beneficial 
in patients who are nauseated by oral agents and do not want 
to take injections [14].
A limitation of this study is its relatively small sample 
size. A larger study population would have strengthened the 
analyses and enhanced the generalizability of its findings.
5  Conclusions
DFN-02 was significantly more effective than placebo in 
reducing migraine-related functional disability. Subjects’ 
satisfaction with DFN-02 was significantly superior to pla-
cebo at 2 and 24 h postdose. There was also greater satis-
faction with DFN-02 compared with the subjects’ pre-study 
usual migraine medication. Subjects treated with DFN-02 
experienced few TEAEs and no SAEs, and there were no 
withdrawals due to safety or tolerability. DFN-02 intranasal 
spray, which combines 10 mg of sumatriptan with a permea-
tion-enhancing excipient, was effective and well tolerated in 
the acute treatment of adults with episodic migraine.
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